Microbot Medical Inc.
MBOT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.04 | -0.12 | -0.20 |
| FCF Yield | -50.52% | -51.21% | -53.23% | -17.68% |
| EV / EBITDA | -1.28 | -1.36 | -1.50 | -3.58 |
| Quality | ||||
| ROIC | -313.26% | -200.18% | -165.31% | -75.41% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.79 | 0.88 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -3.34% | 26.36% | -23.45% | -28.33% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.21 | 0.15 | 1.13 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -2.52 | 0.00 | 0.00 |
| Cash Conversion Cycle | -661.81 | -1,373.92 | -415.10 | -1,339.93 |